O
Oisin Biotechnologies
A platform drug development company focused on creating drugs to combat a variety of age related diseases
About Oisin Biotechnologies
Oisin Biotechnologies is a pioneering company in the biotechnology sector, focusing on developing advanced therapies to combat age-related conditions. The company leverages its proprietary Proteo Lipid Vehicle (PLV) technology, which allows for extensive distribution of DNA and RNA payloads beyond the liver and enables safe, repeated dosing. Oisin's core programs aim to address frailty by stimulating muscle growth, selectively eliminating fat cells, and removing senescent cells, which are cells that have stopped dividing and contribute to aging and various diseases. Oisin Biotechnologies primarily serves the healthcare and pharmaceutical markets, targeting patients suffering from age-related conditions and diseases. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potentially direct sales of its therapeutic solutions. The company operates in a highly specialized market, focusing on innovative solutions that address significant unmet medical needs. By utilizing its unique PLV technology, Oisin aims to provide safer and more effective treatments compared to traditional viral delivery methods.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Seattle, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 73.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Longevity, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $15M | $60M | AbbVie | ↗ |
| SEED✓Equity / VC | May 2021 | $5M | $20M | Althea Group · Althea Group Ventures | — |
Growth signals
Latest recorded traffic for Oisin Biotechnologies is 1.4K monthly website visits, down 26.3% over the last three months. Oisin Biotechnologies's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Kizoo
Althea Group Ventures
Althea Group
Series A1 investor entered at this stage
AbbVie
Other known investors5 additional known investors
Healthspan Capital
Joyo Wijaya
Kingsley Advani
Sergio Ruiz
Westcott LLC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oisin Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oisin Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.